Dose-dependent Cortical Thinning After Partial Brain Radiation in High-grade Glioma

Running title: Dose-related cortical atrophy in glioma

Abstract

Purpose: Radiation-induced cognitive deficits may be mediated by tissue damage to cortical regions. Volumetric changes in cortex can be reliably measured using high-resolution magnetic resonance imaging (MRI). We used these methods to study the association between radiation therapy (RT) dose and change in cortical thickness in high-grade glioma (HGG) patients.

Methods and Materials: We performed a voxel-wise analysis of MR imaging from 15 HGG patients who underwent fractionated partial brain RT. Three-dimensional MRI was acquired pre- and 1-year post-RT. Cortex was parcellated with well-validated segmentation software (Freesurfer). Surgical cavities were censored. Each cortical voxel was assigned a change in cortical thickness between time points, RT dose value, and neuroanatomic label by lobe. Effect of dose, neuroanatomic location, age, and chemotherapy on cortical thickness was tested using linear mixed effects (LME) modeling.

Results: Cortical atrophy was seen after 1-year post RT, with greater effects at higher doses. Estimates from LME modeling showed that cortical thickness decreased by -0.0033 mm ($p < 0.001$) for every 1 Gy increase in RT dose. Temporal and limbic cortex exhibited the largest change in cortical thickness per Gy, compared to other regions ($p < 0.001$). Age and chemotherapy were not significantly associated with cortical thickness change.

Conclusions: We found dose-dependent thinning of the cerebral cortex, with varying neuroanatomical regional sensitivity, one year after fractionated partial brain RT. The magnitude of thinning parallels one-year atrophy rates seen in

neurodegenerative diseases, and may contribute to cognitive decline following high-dose RT.

Introduction

Radiation therapy (RT) is considered standard of care in the treatment of primary brain tumors, but can cause devastating late deficits in neurocognitive function^{1,2}. Despite substantial advancements in high-precision radiation treatment planning and delivery, large amounts of normal-appearing cerebral tissue will be incidentally irradiated³. Identifying critical neuroanatomic structures that undergo radiation-induced damage may shed light on the complicated pathogenesis of radiation-induced neurocognitive decline, and may offer the possibility of cognitive sparing via selective sparing of these structures.

Quantitative magnetic resonance imaging (MRI) can be used to probe anatomic brain microstructure with high spatial resolution⁴. Radiation-induced imaging changes, as detected with quantitative MRI, have been correlated with structural changes in cerebral tissue in animal models⁵. Most imaging studies have focused on quantifying radiation-induced damage within the cerebral white matter or the hippocampus^{6,7}. Associations between cortical regions and neurocognitive functions such as memory and semantic processing⁸ are clear, but data is sparse on the effects of radiation on cerebral cortex^{9,10}

Recent advances in quantitative MRI and automatic segmentation have streamlined the complete parcellation of the cerebral cortex¹¹. These methods can be used to generate accurate, automated measurements of cortical thickness at each point on the cortical surface, rivaling measurements by postmortem histopathology^{12–14}. Such tools have been used extensively in the study of cortical atrophy in neurodegenerative diseases^{15,16} including Alzheimer's

disease (AD) and mild cognitive impairment¹⁷. Similar analyses of cortical degeneration in patients undergoing partial brain RT may improve our understanding of radiation-induced tissue injury and cognitive decline.

In this study, we investigate the relationship between radiation dose and changes in cerebral cortical thickness in patients treated for high-grade glioma (HGG) with partial brain RT, accounting for potential confounders such as neuroanatomical location, age, and chemotherapy. For the purposes of this study, cerebral cortex is confined to neocortical regions in the brain that consist of 6 cell layers. The analysis does not consider phylogenetically older regions, consisting of three or four cell layers such as the olfactory cortex and hippocampus¹⁸.

Methods and Materials

Patients

The retrospectively studied cohort consists of fifteen consecutively treated HGG patients who underwent fractionated partial brain radiotherapy at XXXX between 2011- 2013. From January 2011 to December 2013, thirty-two patients with primary HGG tumors treated with fractionated brain RT underwent a standardized MRI imaging protocol prior to RT on the same 3 Tesla MR system in our institution's cancer center. From this group, twenty-two patients were selected that had been imaged 1-year post-RT with no intervening additional radiation. Among these, seven patients were excluded from the analysis due to significant anatomical changes (large surgical resection (n=3), tumor growth

(n=4)) over the course of the year, which prevented accurate imaging correspondence between the two time points. This study was approved by the institutional review board.

MR Imaging

MR imaging was performed on a 3T Signa Excite HDx scanner (GE Healthcare, Milwaukee, Wisconsin) equipped with an 8-channel head coil. The imaging protocol included pre- and post-contrast 3D volumetric T1-weighted inversion recovery spoiled gradient-echo sequence (TE, 2.8 ms; TR, 6.5 ms; TI, 450 ms) and a 3D T2-weighted FLAIR sequence (TE, 126 ms; TR, 6000 ms; TI, 1863 ms). Before analysis, all MR images were processed to correct for geometric distortions¹⁹. The T1-weighted precontrast images were rigidly co-registered to the treatment planning CT images using in-house software²⁰ developed in MATLAB (MathWorks, Natick, Massachusetts). The registered images were visually inspected for accuracy after which, the transformation matrix was used to resample the radiation dose maps, calculated on the treatment planning CT, to the MR imaging space.

Cortical Thickness

Cortical thickness was estimated using Freesurfer (version 5.3; available at <http://surfer.nmr.harvard.edu>) and the T1-weighted precontrast images, weighted by T2-weighted FLAIR to correct for regions of edema or hypointensity^{21,22}. Cortical thickness is calculated at each vertex of the

reconstructed cortical mantle as the distance between the white matter and pial surfaces²³. The Freesurfer processing pipeline was run independently for each time point (pre-RT and 1-year post-RT). The 1-year post-RT cortical surface was resampled onto the baseline surface using the “mri_surf2surf” Freesurfer function.

After temporal correspondence was established, 1-year change in cortical thickness was calculated as the difference in thickness between the pre- and 1-year post-RT time points for each vertex of the baseline cortical surface. Since a voxel includes many vertices, all vertices were then grouped by voxel location. Thus, the 1-year change in cortical thickness for each cortical voxel represented the average change in cortical thickness of all the vertices located within that voxel. The radiation dose at each voxel was determined by sampling the co-registered dose map at that location. Each voxel was also assigned an anatomic location (frontal, temporal, occipital, parietal, or limbic). An example of the cerebral cortex segmented on MR images is shown in Figure 1A with the neuroanatomical locations used in this study illustrated in Figure 1B. Surgical scars, tumors, tumor beds, and resection cavities were censored from analyses, to mitigate mislabeling of cortex, and all images were inspected for errors in segmentation. For patients with intervening surgeries between the two time points, the new tumor cavity was also censored from analyses.

Statistical Analysis

The data consisted of a large number of voxels (>100,000) per patient, which provided substantial power to evaluate the primary dependent variable. As an initial step, voxels were grouped by patient and anatomic location. A segmented linear regression analysis, using maximum likelihood, was conducted to test whether the relationship between dose and patient-averaged cortical atrophy could be separated into 2 intervals with different slopes by a breakpoint dose. Confidence intervals were estimated using profile likelihood. We next performed linear mixed effects (LME) modeling on the effect of radiation dose on 1 year change in cortical thickness at each voxel considering cortical location (categorical variable), age (continuous variable) and chemotherapy (temozolomide vs temolozolomide + other) as potential covariates²⁴. All possible interaction terms were tested. To control for correlated observations within subjects, we tested a subject-specific random slope and intercept for dose. With the addition of each random effects term, the model was tested using a likelihood ratio test. Estimation of fixed effects parameters was based on restricted maximum likelihood. Main effects and interaction terms were significant at $p < 0.05$. Statistical analyses were performed using R environment for statistical computing ("lme4" package, version 1.1-7)²⁵.

Results

Patient Characteristics

Patient, tumor, and treatment characteristics are shown in Table 1. The cohort consisted of 10 males and 5 females with a median age of 60 years. Most

patients had glioblastoma and median tumor size pre-operatively was 3.3 cm. The majority of patients were treated with concurrent and adjuvant temozolomide with or without additional standard or investigational therapies as described in Table 1. Five patients had intervening surgeries between the two time points, of which four were due to tumor recurrence.

Whole-brain dose response

Voxel-wise 1-year change in cortical thickness (by patient and averaged) is shown in Figure 2. The average change in thickness increased in magnitude with increasing dose, from a value of -0.02 mm at 1 Gy to -0.30 mm at 60 Gy. Using the segmented linear regression analysis, a breakpoint of 34.6 Gy [95% CI: 31.9, 39.9] separated the cortical atrophy-dose relationship into two linear segments with slopes of -0.0013 mm/Gy [95% CI: -0.00089, 0.0017] and -0.0078 mm/Gy [95% CI: -0.0072, -0.0084], before and after the breakpoint respectively. The adjusted R-squared of the model was 0.96, compared to 0.92 when a continuous linear regression model using a single slope was used to fit the data.

Variation in dose-response with anatomic location

The dose-associated cortical thinning for each neuroanatomic location (frontal, temporal, parietal, occipital, and limbic lobe) is shown in Figure 3 A-E. The solid line in each panel represents a linear univariable regression of the location-specific change in thickness as a function of radiation dose. All locations showed similar trends of increased cortical thinning with increasing radiation

dose. The slopes of the univariable linear regression, in mm/Gy, were calculated for the five locations as: frontal (-0.0024, 95% CI: -0.0022,-0.0027), temporal (-0.0046, 95% CI: -0.0043, 0.0049), occipital (-0.0025, 95% CI: -0.0021,-0.0028), parietal (-0.0029, 95% CI: -0.0024, -0.0033), and limbic (-0.0034, 95% CI: -0.0025, -0.0033). The effect of the neuroanatomic location of the applied dose on cortical thinning was further analyzed using linear mixed effects modeling on the full dataset.

Linear Mixed Modeling of Cortical Atrophy

The results of linear mixed-effects modeling, with dose as the main predictor variable and location as covariate, are presented in Table 2. Age and chemotherapy were not significantly associated with the degree of cortical thinning ($p > 0.05$) and were thus excluded from the final model. Occipital cortex was the reference location. Estimates and p -values are shown for each of the main effects and interaction terms. The intercept of the model, 0.0043 mm, corresponds to the atrophy observed in the occipital lobe, controlling for dose. Main effects for other locations (frontal, limbic, temporal, and parietal) are listed and represent the difference in 1-year cortical thinning compared to the occipital lobe.

The dose estimate of the model, -0.0026 mm, corresponds to the rate of cortical thinning observed for every 1 Gy increase in dose within the occipital lobe ($p < 0.001$). The interaction terms between dose and location represent how the rate of thinning with dose among the various locations differs from that of the

occipital lobe. All interaction terms were found to be statistically significant. Temporal and limbic lobes had negative interaction estimates, indicating that the cortical thinning per unit dose was greater in these locations compared to the occipital lobe, while the inverse is true for the frontal and parietal lobes. Increase in atrophy for every 1 Gy increase in dose for each location independent of a reference lobe was calculated as (in mm): frontal (-0.0010, 95 % CI: -0.005,-0.0021), temporal (-0.0053, 95% CI: -0.0041,-0.0063), occipital (-0.0026, 95% CI:-0.0014,-0.0037), parietal (-0.0021, 95% CI: -0.0010,-0.0032), and limbic (-0.0035, 95% CI: -0.0023,-0.0046).

Discussion

Quantification of microstructural changes to normal brain tissue after radiation therapy may help us understand the physiologic processes that underlie radiation-induced neurocognitive decline. Our results show that both radiation dose and neuroanatomic location are significantly associated with cortical thinning at 1-year post-RT in HGG patients. This relationship is illustrated graphically in Figure 4 for an example patient. The cortical surface is overlaid with color maps representing radiation dose (Figure 4a) and cortical thinning (Figure 4b) values at 1-year post-RT. Regions of cortex that received higher radiation dose (color coded, yellow) coincide with those showing greater degree of cortical thinning (color coded, light blue).

A segmented linear regression analysis tested for the presence of a breakpoint dose, which separated the patient-averaged cortical atrophy-dose

relationship at 34.6Gy into 2 intervals with different regression coefficients (slope). However, the very modest increase in adjusted R-squared of the segmented model compared to a continuous linear regression model (0.96 vs 0.92) suggests the latter may be sufficient in explaining the relationship. Dose-associated cortical thinning also varied by neuroanatomic location. In particular, the temporal and limbic lobes exhibited the greatest rate of cortical loss with radiation dose. To our knowledge, this is the first study to establish a quantitative association between regional cortical atrophy and radiation dose in adult patients treated for brain tumors.

Volumetric cortical analysis has been previously investigated in pediatric patients treated for medulloblastoma²⁶ with chemotherapy and radiation. Cortical thickness of these patients was found to be between 0.23 and 0.39 mm thinner than age- and gender-matched controls. These values are similar to the cortical thinning observed in the present study at the higher dose ranges (-0.3 mm). However, cortical thinning reported in the pediatric study represents a difference between two groups whereas the values reported in the present study represent longitudinal change within the same patient cohort. Cortical thinning in the pediatric population²⁶ was predominantly found in the posterior portion of the brain, such as the parieto-occipital and lateral temporal lobes. The authors hypothesize that these areas of cortex overlap with those undergoing active development in children and are therefore most sensitive to the effects of radiation. In the present study, the temporal lobe was also determined to be the most radiosensitive neuroanatomic location in adults, although one would expect

the underlying radiobiological process responsible to be different from that hypothesized for the pediatric population.

The cellular basis for radiation-associated cortical thinning in the brain is not well understood. The cerebral cortex consists primarily of neuronal cells (pyramidal and granular), neuroglial cells (astrocytes, oligodendroglial) and capillaries²⁷. A recent study²⁸ suggested that vascular endothelial cells are the primary target for radiation necrosis of the cortex. However, this study was performed on animals using a single irradiation of 25 Gy, which likely elicits a different radiobiological response than the fractionated radiation therapy used in our study. While there has been no study to demonstrate the dose-response of vascular endothelial cells in the cortex, irradiation of rat spinal cord tissue has shown dose-dependent loss in the number of endothelial cells²⁷. Radiation-associated decrease in vascular density may therefore result or be involved in neuronal degeneration, which could subsequently manifest macroscopically as a decrease in cortical thickness. There are studies showing comparable decreases in vascular density in AD²⁹. While the mechanism by which neurodegenerative disease and RT affect cortical vasculature may differ, the downstream influence on cortical thickness may be similar. For example, a recent study demonstrated that exposure of cultured primary neurons to radiation increased tau phosphorylation at several sites, similar to changes observed in AD³⁰.

The magnitude of radiation-associated cortical thinning can be better appreciated by comparison with values reported in the literature for other conditions. The thinning observed in the highest dose regions (0.3 mm) at 1-year

post-RT in our analysis is greater than the annual rate observed in AD patients of 0.07-0.1 mm^{31,32}. In the spectrum of neurodegenerative diseases (including mild cognitive impairment and other dementia subtypes), Alzheimer's disease (AD) is typically associated with a high degree of cortical degeneration¹⁵. By comparison, the annual rate of cortical loss observed in a control population, due to normal aging, has been reported to be on average 0.01 – 0.02 mm³³. Therefore, the magnitude of cortical thinning observed in our cohort, using well-validated cortical volumetric methods may represent a pathologic degree of atrophy.

We found that the sensitivity of cerebral cortex to radiation-induced atrophy varies by anatomic location. One possible explanation for this phenomenon is the difference in the cellular composition of different portions of the brain. Regional patterns of degeneration are also widely reported in neurodegenerative diseases²². In AD, for example, cortical atrophy and neuronal cell loss were found to be most severe in the medial temporal lobe and limbic areas³⁴. This commonality in location of greatest cortical atrophy in AD and RT suggests that, while the underlying biological pathogenesis may differ, there may exist an inherent cellular property that makes some regions of cortex more vulnerable to injury than others. It is important to note that although the patterns of cortical atrophy post-RT are comparable to those seen in AD, the prognosis for these two sets of patients is quite different, and this work is not intended to suggest that patients receiving high-dose RT will develop AD.

Due to the small sample size and relatively homogenous population of the cohort, the effects of chemotherapy could not be well-controlled for in this study.

When we grouped the cohort by standard temozolomide versus temozolomide and other adjuvant therapy, we did not observe a difference in 1-year cortical thinning. Chemotherapy has been previously associated with structural changes in cerebral white matter and cognitive function³⁵, suggesting that similar trends may be found with cortical thickness. It is possible that concurrent and adjuvant chemotherapy may potentiate the effects of radiation dose on cortical atrophy.

This study has other limitations. The patient sample size is small; however the quantitative, voxel-wise analysis affords considerable power to detect changes in cortical thickness by voxel. Also, cortical thickness changes in this cohort were not tested against a control population of patients with HGG who did not receive radiotherapy. Thus, thinning of the cortex cannot be definitively attributed to brain RT as the biologic effect of HGG itself on the cellular makeup of cortical tissue is unclear. The effect of intervening surgeries or tumor recurrence also remains unclear. However, cortical changes were observed in areas of normal-appearing brain, suggesting direct tumor or surgery effect would be less likely than other explanations.

The effect of edema on cortical thickness measurements is unknown, and is a limitation of imaging analysis in high-grade glioma patients. In addition, the preponderance of temporal lobe tumors will have likely resulted in a larger sample of high-dose temporal lobe voxels. This may have consequently given us greater power to detect high-dose related changes in the area. Finally, the segmentation tool used in this study (Freesurfer) was developed and validated in non-tumor patients and is currently being validated for use in brain tumor

populations. To help mitigate these effects, a single radiation oncologist manually checked all cortical segmentations from each of the subjects. Also, cortical scars, tumor beds and resection cavities that could potentially be mislabeled were censored.

While the present study showed dose-dependent cortical thinning with brain radiotherapy, it remains to be seen whether these changes at the voxel level have implications on neurocognitive function. Future studies on radiation-associated cortical thickness changes should incorporate neurocognitive outcomes, and prospective studies of this kind are currently underway at our institution. This may help establish correspondence between domain-specific neurocognitive decline and radiation-associated atrophy in corresponding cortical regions.

Conclusion

Dose-dependent thinning of the cerebral cortex was observed in patients treated for HGG with fractionated partial brain radiotherapy. Cortical thinning was also found to vary by neuroanatomical location. The magnitude and regional specificity of cortical degeneration observed at 1-year post-therapy parallels neurodegenerative diseases such as AD. Future studies will attempt to further characterize this effect, as well as to correlate RT-associated changes in cortical thickness with changes in neurocognitive function. This information may prove vital to developing new dose-safety guidelines for minimizing the detrimental effects of brain radiotherapy and improving patient quality of life.

Acknowledgements

This work was partially supported by the following grants: National Institutes of Health Grant KL2RR031978, KL2TR00099, UL1TR000100, American Cancer Society Pilot Award ACS-IRG #70-002, National Science Foundation Grant 1430082.

References

1. McDuff SGR, Taich ZJ, Lawson JD, et al. Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. *J Neurol Neurosurg Psychiatry*. 2013;84(12):1384-1391.
2. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. *J Clin Oncol*. 2006;24(8):1305-1309.
3. Steen RG, Koury B S M, Granja CI, et al. Effect of ionizing radiation on the human brain: white matter and gray matter T1 in pediatric brain tumor patients treated with conformal radiation therapy. *Int J Radiat Oncol Biol Phys*. 2001;49(1):79-91.
4. Mori S, Crain BJ, Chacko VP, van Zijl PC. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. *Ann Neurol*. 1999;45(2):265-269.
5. Wang S, Wu EX, Qiu D, Leung LHT, Lau H-F, Khong P-L. Longitudinal diffusion tensor magnetic resonance imaging study of radiation-induced white matter damage in a rat model. *Cancer Res*. 2009;69(3):1190-1198.
6. Nagesh V, Tsien CI, Chenevert TL, et al. Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. *Int J Radiat Oncol Biol Phys*. 2008;70(4):1002-1010.
7. Corn BW, Yousem DM, Scott CB, et al. White matter changes are correlated significantly with radiation dose: Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). *Cancer*. 1994;74:2828-2835.
8. Van Der Flier WM, Middelkoop HAM, Weverling-Rijnsburger AWE, et al. Neuropsychological correlates of MRI measures in the continuum of cognitive decline at old age. *Dement Geriatr Cogn Disord*. 2005;20:82-88.
9. Raju U, Gumin GJ, Tofilon PJ. Radiation-induced transcription factor activation in the rat cerebral cortex. *Int J Radiat Biol*. 2000;76(8):1045-1053.
10. Asai A, Matsutani M, Kohno T, et al. Subacute brain atrophy after radiation therapy for malignant brain tumor. *Cancer*. 1989;63:1962-1974.

11. Dale AM, Fischl B, Sereno MI. Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction. *Neuroimage*. 1999;194:179-194.
12. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. *Neuroimage*. 1999;9(2):195-207.
13. Kuperberg GR, Broome MR, McGuire PK, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. *Arch Gen Psychiatry*. 2003;60(9):878-888.
14. Fjell AM, Westlye LT, Amlien I, et al. High consistency of regional cortical thinning in aging across multiple samples. *Cereb Cortex (New York, NY 1991)*. 2009;19(9):2001-2012.
15. Seo SW, Im K, Lee JM, et al. Cortical thickness in single- versus multiple-domain amnesic mild cognitive impairment. *Neuroimage*. 2007;36(2):289-297.
16. Kemmotsu N, Girard HM, Kucukboyaci NE, et al. Age-related changes in the neurophysiology of language in adults: relationship to regional cortical thinning and white matter microstructure. *J Neurosci*. 2012;32(35):12204-12213.
17. Fennema-Notestine C, Hagler DJ, McEvoy LK, et al. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. *Hum Brain Mapp*. 2009;30(10):3238-3253.
18. Creutzfeldt OD. *Cortex Cerebri*. Oxford University Press; 1995.
19. Jovicich J, Czanner S, Greve D, et al. Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data. *Neuroimage*. 2006;30(2):436-443.
20. Kothari PD, White NS, Farid N, et al. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. *AJNR Am J Neuroradiol*. 2013;34(9):1752-1757.
21. Du A-T, Schuff N, Kramer JH, et al. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. *Brain*. 2007;130(Pt 4):1159-1166.
22. McDonald CR, Gharapetian L, McEvoy LK, et al. Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. *Neurobiol Aging*. 2012;33(2):242-253.

23. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proc Natl Acad Sci U S A*. 2000;97(20):11050-11055.
24. Laird NM, Ware JH. Random-Effects Models for Longitudinal Data. 2007;38(4):963-974.
25. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2013.
26. Liu AK, Marcus KJ, Fischl B, et al. Changes in cerebral cortex of children treated for medulloblastoma. *Int J Radiat Oncol Biol Phys*. 2007;68(4):992-998.
27. Wong CS, Van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. *Mol Interv*. 2004;4(5):273-284.
28. Lyubimova N, Hopewell JW. Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation-induced CNS injury. *Br J Radiol*. 2004;77(December 2003):488-492.
29. Buee L, Hof P, Delacourte A. Brain Microvascular Changes in Alzheimer's Disease and Other Dementias. *Ann N Y Acad Sci*. 1997;826:7-24.
30. Li L, Wang W, Welford S, Zhang T, Wang X, Zhu X. Ionizing radiation causes increased tau phosphorylation in primary neurons. *J Neurochem*. 2014;131:86-93.
31. Thompson PM, Hayashi KM, Zubicaray G De, et al. Dynamics of Gray Matter Loss in Alzheimer ' s Disease. *J Neurosci*. 2003;23(3):994-1005.
32. Subancu MR, Desikan RS, Sepulcre J, et al. The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease. *Arch Neurol*. 2014;68(8):1040-1048.
33. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. *Cereb Cortex*. 2004;14(7):721-730.
34. Brun A, Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. *Histopathology*. 1981;5:549-564.
35. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its

correlation with impaired cognitive functioning. *J Clin Oncol.* 2012;30(3):274-281.

Figure Legends

Figure 1. A) Cortical segmentation of left hemisphere overlaid on T1-weighted pre-contrast MR sagittal, axial, and coronal images. B) Neuroanatomical labels are shown in color on the left pial surface

Figure 2. Patient-specific (gray lines) and patient-averaged (blue diamond data points) 1-year change in cortical thickness for radiation doses from 0 to 60 Gy.

Figure 3. Relationship between 1-year change in cortical thickness and radiation dose for A) frontal, B) temporal, C) occipital, D) parietal, and E) limbic lobes.

Error bars are standard errors. The solid line represents the result of the univariable regression. The limbic, temporal, and parietal lobes exhibited the steepest rate of change of cortical thickness with dose.

Figure 4. Cortical surface representation of a) radiation dose in Gy and b) cortical thinning at one year observed in an example patient. Regions receiving higher dose show greater degree of cortical thinning at 1-year post-RT.

Table 1. Patient, tumor, and treatment characteristics (n=15)

Characteristic	Number of patients (%)
Gender	
Male	10 (66.7)
Female	5 (33.3)
Age (years), median (range)	60 (40-77)
Tumor Histology	
Glioblastoma	14 (93.3)
Anaplastic ganglioglioma	1 (6.7)
Pre-operative tumor size (largest dimension, cm), median (range)	3.3 (1.0–7.7) 162.7 (59.8 – 571.3)
Planning Target Volume (cc), median (range)	
Tumor location:	
Temporal	8 (66.7)
Frontal	2 (13.3)
Frontotemporal	1 (6.7)
Parietal	1 (6.7)
Parietotemporal	2 (13.3)
Parietooccipital	1 (6.7)
Surgery	
Gross total resection	11 (73.3)
Subtotal resection	4 (26.7)

RT Dose (fraction size) (Gy)

60 (2)	13 (86.7)
60 (3)	1 (6.7)
59.4 (1.8)	1 (6.7)

Concurrent chemotherapy:

Temozolomide only	9 (60.0)
Temozolomide + vaccine trial [#]	4 (26.7)
Temozolomide + other clinical trial [†]	2 (13.3)

Adjuvant chemotherapy:

Temozolomide only	5 (33.3)
Temozolomide + other chemotherapy	4 (26.7)
Temozolomide + bevacizumab	2 (13.3)
Temozolomide + other clinical trial [°]	2 (13.3)
Temozolomide + vaccine trial [‡]	1 (6.7)
No adjuvant Chemotherapy	1 (6.7)

[#] vaccine trial targeting tumor antigens (n=2); vaccine trial of activated dendritic cells (n=2)

[†] α_v integrin inhibitor trial(n=1); poly ADP ribose polymerase (PARP) inhibitor trial(n=1)

^{||} lapatinib, rapamycin, lomustine, irinotecan, carboplatin

[°] poly ADP ribose polymerase (PARP) inhibitor trial(n=2)

[‡] vaccine trial of activated dendritic cells (n=1)

Table 2. Linear mixed-effects model estimates for changes in cortical thickness with dose as the main predictor variable and location as a covariate

Characteristic	Estimate	<i>p</i>
Dose	-0.0026	<0.001
Location		
Occipital (reference)	0.0043	0.81
Frontal	-0.023	<0.001
Limbic	0.037	<0.001
Temporal	-0.0038	0.13
Parietal	0.000041	0.94
Interaction		
Frontal - Dose	0.0015	<0.001
Limbic - Dose	-0.00095	<0.001
Temporal - Dose	-0.0027	<0.001
Parietal - Dose	0.00045	<0.001